NCT03603158

Brief Summary

Methadone maintenance therapy (MMT) is one of the modalities to prevent HIV transmission among injected drug users, particularly in opioid-dependent users. However, methadone-associated cardiotoxicity is one of the fatal adverse events that limit the widespread usage in certain groups of opioid-dependent patients. This is a cross-sectional study aimed to investigate the association between 4 KCNH2 SNPs (1539C\>T, in exon 6 of KCNH2 gene; 1956T\>C, in exon 8 of KCNH2 gene), 2350C\>T (in exon 9 of KCNH2 gene), 2690A\>C (Exon 11 of KCNH2 gene)) and prolongation of QTc interval in opioid-dependent Kelantanese Malays who are the recipients of Methadone Maintenance Therapy. The investigators hypothesized that subjects with minor alleles of those 4 SNPs will have longer QTc intervals than those with major alleles, adjusting for the effects of other confounding factors such as age and gender of the subjects, plasma methadone trough levels, hypokalemia, hypocalcemia and hypomagnesemia. The investigators also aimed to provide a model that will reliably predict the magnitude QTc based on the SNPs data and other covariates mentioned above. This will greatly assist in identifying methadone recipients who are at risk of developing prolonged QTc or the more fatal torsade de pointes.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Feb 2011

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2012

Completed
5.5 years until next milestone

First Submitted

Initial submission to the registry

July 18, 2018

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 27, 2018

Completed
Last Updated

July 30, 2018

Status Verified

July 1, 2018

Enrollment Period

1.9 years

First QC Date

July 18, 2018

Last Update Submit

July 26, 2018

Conditions

Keywords

HERGKCNH2METHADONEOPIOID

Outcome Measures

Primary Outcomes (1)

  • QTc Interval

    QT interval (measured in milliseconds) obtained from ECG reading that is then divided by the shortest R-R interval to the power of 0.33 (Fredericia's formula).

    First screening visit

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Kelantanese Malay opioid-dependent subjects who were on Methadone Maintenance Therapy (MMT) in the Eastern-coastal state of Kelantan, Malaysia.

You may qualify if:

  • Opioid-dependent subjects aged 18 years and above
  • Opioid-dependent subjects who were on Methadone Maintenance Therapy (MMT) for 6 months or longer and had stable plasma methadone concentration
  • Malay ancestry up to 3 generations
  • A history of good compliance with Directly-Observed Therapy (DOT)

You may not qualify if:

  • Opioid-dependent subjects who were aggressive and had active psychiatric illnesses
  • Opioid-dependent subjects with chronic medical and surgical illnesses
  • Opioid-dependent subjects with cardiac structural defects
  • Inability to communicate in Malay or English

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universiti Sains Malaysia

Kubang Kerian, Kelantan, 15350, Malaysia

Location

Related Publications (2)

  • Koo SH, Ho WF, Lee EJ. Genetic polymorphisms in KCNQ1, HERG, KCNE1 and KCNE2 genes in the Chinese, Malay and Indian populations of Singapore. Br J Clin Pharmacol. 2006 Mar;61(3):301-8. doi: 10.1111/j.1365-2125.2005.02545.x.

  • Hajj A, Ksouda K, Peoc'h K, Curis E, Messali A, Deveaux LL, Bloch V, Prince N, Mouly S, Scherrmann JM, Lepine JP, Laplanche JL, Drici MD, Vorspan F. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend. 2014 Aug 1;141:34-8. doi: 10.1016/j.drugalcdep.2014.04.027. Epub 2014 May 14.

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Genomic DNA extracted from peripheral leukocytes in 5 mls venous blood samples provided by all methadone recipients enrolled in this study.

MeSH Terms

Conditions

Opioid-Related Disorders

Condition Hierarchy (Ancestors)

Narcotic-Related DisordersSubstance-Related DisordersChemically-Induced DisordersMental Disorders

Study Officials

  • Muslih AbdulKarim Ibrahim, PhD

    Hawler University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

July 18, 2018

First Posted

July 27, 2018

Study Start

February 1, 2011

Primary Completion

December 31, 2012

Study Completion

December 31, 2012

Last Updated

July 30, 2018

Record last verified: 2018-07

Data Sharing

IPD Sharing
Will not share

Locations